MMRV Combination Vaccine: Why the UK Uses Separate Injections (2026)

The UK childhood schedule gives MMR and varicella as separate injections at 12 months — here is the febrile-seizure evidence that drives that choice.

The UKHSA announced in 2023 that varicella vaccination would be added to the routine childhood schedule, with implementation in 2026. When it arrives, parents and pharmacy teams will see something that looks unfamiliar to anyone who has studied the US schedule: the UK is not using the MMRV combination vaccine at the 12-month dose. Instead, MMR and varicella are given as separate injections at the same visit. Here is why.

The febrile seizure signal

In 2006 the US Centers for Disease Control's Vaccine Safety Datalink detected an approximate doubling of febrile seizure risk in the 5–12 days after the first MMRV dose at 12–23 months, compared with separate MMR and varicella injections at the same visit. The absolute rate — roughly 9 additional febrile seizures per 10,000 MMRV doses — was small but statistically clear.

The CDC's Advisory Committee on Immunization Practices (ACIP) subsequently updated its recommendation: separate MMR and varicella injections remain the preferred option at the 12–15-month first dose, with MMRV offered only when parents specifically request it after counselling. For the 4–6-year booster dose, MMRV is preferred.

Europe's experience has been broadly consistent. The 2016 EUvac.net evaluation and subsequent post-marketing surveillance reports by the EMA found the same signal. Germany, Austria and several other countries give MMRV routinely but counsel parents on the small excess risk; the UK's JCVI, when it modelled the UK schedule, came to the view that separate injections at 12 months minimise the population-level febrile seizure burden without any loss of seroconversion.

What the JCVI recommendation actually says

The JCVI's 2023 advice, confirmed by the UK four CMOs, is:

First dose (12 months): MMR vaccine plus varicella vaccine, given as two separate injections in different limbs.
Second dose (3 years 4 months): MMR vaccine plus varicella vaccine, same format — two separate injections.
MMRV combination vaccine is not used in the routine UK schedule.

This is a pragmatic choice: the UK already gives multiple injections per visit routinely (the 6-in-1 at 8 weeks is administered alongside rotavirus, meningococcal B and pneumococcal vaccines), so adding a second injection to an MMR visit was not considered a significant acceptability barrier.

What MMRV vaccines exist

Globally, two MMRV combination vaccines hold licences: ProQuad (Merck, licensed since 2005) and Priorix-Tetra (GSK, licensed since 2006). Both are used widely in Europe and the United States, and both are available on the UK private market where clinicians may prescribe them. The NHS does not use either routinely.

In practice, pharmacy teams supplying private childhood vaccination programmes will occasionally see MMRV on prescriptions. The cold chain, reconstitution and administration are similar to MMR and varicella separately, but the febrile-seizure counselling is an explicit part of the consent process.

Parent questions pharmacy teams will hear

Why two injections instead of one? The combined MMRV vaccine carries a small but measurable increase in febrile seizure risk at the first dose; separate injections avoid that excess without reducing protection.

Can we ask for MMRV privately? Yes. It is available on private prescription in the UK. Parents should understand the febrile seizure signal is age-specific (12–23 months, first dose) and that the absolute risk remains low.

Does this mean MMR or varicella is dangerous? No. Both vaccines are well established, MMR has decades of data and varicella vaccination has been routine in the US since 1995. The febrile seizure signal is specifically a combination-vaccine issue, not an MMR or varicella issue.

Will my child get chickenpox anyway? Varicella vaccine prevents around 90–95% of any chickenpox and close to 100% of severe chickenpox. Breakthrough cases are milder than natural infection and less contagious.

Can the varicella injection be given at another visit? JCVI's recommendation is that both be given at 12 months to match the seroconversion window for varicella. Delaying risks exposure before protection is established.

The second dose and school entry

The UK schedule gives a second MMR and varicella dose at the 3-year 4-month pre-school booster visit, again as separate injections. The JCVI chose not to follow the US pattern of preferring MMRV at the 4–6-year booster, primarily to simplify practice guidance and maintain the consistent "separate injections" message across both doses.

Operational notes for pharmacy

Cold chain: varicella vaccine is more heat-sensitive than MMR and must remain at 2–8°C; any excursion should be reported through the usual fridge protocol.
Reconstitution: both MMR and varicella are lyophilised and must be reconstituted immediately before administration. Discard within the time window on the SmPC.
Injection sites: give in different limbs to simplify reaction attribution if local reactions occur.
Post-vaccination advice: mild fever, malaise and occasionally a mild varicella-like rash 7–21 days after the varicella dose. Paracetamol can be used for fever; ibuprofen is also acceptable after age 3 months with usual precautions. Do not give aspirin in any child under 16 (Reye's syndrome risk).
Immunosuppression exclusions: live vaccines (both MMR and varicella) are contraindicated in significant immunosuppression — check Green Book chapters before administration.

Where this sits in UK pharmacy

Vaccination has become one of the fastest-growing clinical services in community pharmacy, with flu, travel, shingles and now varicella likely to expand the category further. PharmSee's pharmacy directory lists the contractor network delivering these services, and our pharmacist and clinical pharmacy jobs reflect rising employer demand for vaccinators across NHS and private pathways.

Caveats

This article summarises the Green Book Chapters 21 (measles, mumps and rubella) and 34 (varicella), JCVI recommendations and UKHSA communications as of April 2026. The schedule is dynamic and exact dose timings may be updated. Always defer to the current Green Book chapter and any PSD or PGD in force at your setting.